Antiviral Drugs - Poland

Poland

In Poland, the revenue in the Antiviral Drugs market is expected to reach €129.00m by 2024.
The market is projected to show an annual growth rate (CAGR 2024-2029) of 1.34%, which will result in a market volume of €137.90m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to €28,120.00m in 2024.
Poland's antiviral drug market is experiencing a surge in demand due to the country's proactive approach to public health and increasing awareness about the importance of preventive measures.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for antiviral drugs in Poland has been increasing steadily in recent years.

Customer preferences: The preference for antiviral drugs in Poland has been influenced by the increasing awareness of viral infections and their impact on public health. Customers in Poland are increasingly looking for antiviral drugs that offer a broad-spectrum of activity against different types of viruses. Additionally, customers are looking for drugs that are effective against emerging viral infections.

Trends in the market: One of the major trends in the antiviral drugs market in Poland is the increasing use of combination therapies. Combination therapies involve the use of two or more antiviral drugs to increase the effectiveness of treatment. This trend has been driven by the need to combat drug resistance and to improve treatment outcomes for patients.Another trend in the market is the increasing use of prophylactic antiviral drugs. Prophylactic drugs are used to prevent viral infections in people who are at high risk of infection. This trend has been driven by the increasing number of people who are at risk of viral infections due to their occupation or lifestyle.

Local special circumstances: The antiviral drugs market in Poland is characterized by the presence of both local and international pharmaceutical companies. Local companies are focused on developing drugs that are effective against viral infections that are prevalent in Poland, such as influenza and hepatitis. International companies, on the other hand, are focused on developing drugs that are effective against emerging viral infections that have a global impact.

Underlying macroeconomic factors: The increasing demand for antiviral drugs in Poland is driven by several macroeconomic factors. These include the increasing prevalence of viral infections, the aging population, and the increasing healthcare expenditure. The Polish government has also been investing in the development of the healthcare sector, which has led to the availability of better healthcare facilities and services. This has led to an increase in the demand for antiviral drugs as more people are able to access healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.